Search
Search Results
-
Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline
BackgroundDynamic PET imaging studies provide accurate estimates of specific binding, but also measure the relative tracer delivery (R 1 ), which is a...
-
A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images
IntroductionAmyloid-β (Aβ) plaques is a significant hallmark of Alzheimer's disease (AD), detectable via amyloid-PET imaging. The...
-
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
PurposePittsburgh Compound-B ( 11 C-PiB) and 18 F-florbetapir are amyloid-β (Aβ) positron emission tomography (PET) radiotracers that have been used as...
-
Clinical impact of amyloid PET using 18F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
ObjectiveAmyloid positron emission tomography (PET) can reliably detect senile plaques and fluorinated ligands are approved for clinical use....
-
Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer’s disease
PurposeTo determine the association between occipital amyloid-PET uptake and neurocognitive performance in Alzheimer’s disease (AD).
Materials and...
-
Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy
Shortening the amount of time required to acquire amyloid positron emission tomography (PET) brain images while maintaining the accuracy of...
-
Positive rate and quantification of amyloid pathology with [18F]florbetapir in the urban Chinese population
ObjectivesAmyloid deposition is considered the initial pathology in Alzheimer’s disease (AD). Personalized management requires investigation of...
-
18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
PurposeRecent evidence suggests that PET imaging with amyloid-β (Aβ) tracers can be used to assess myelin integrity in cerebral white matter (WM)....
-
Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies
PurposeThe simplified reference tissue model (SRTM) is commonly applied for the quantification of brain positron emission tomography (PET) studies,...
-
Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis
PurposeThe clinical diagnosis of pulmonary involvement in individuals with systemic AL amyloidosis remains challenging. [ 18 F]florbetapir imaging has...
-
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
PurposeWe evaluated myelin changes throughout the central nervous system in Multiple Sclerosis (MS) patients by using hybrid [ 18 F]florbetapir PET-MR...
-
Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
PurposeVisual reading of 18 F-florbetapir positron emission tomography (PET) scans is used in the diagnostic process of patients with cognitive...
-
Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state
PurposePositron emission tomography (PET) imaging with amyloid-beta (Aβ) tracers and 2-[18F] fluoro-2-Deoxy- d -glucose ( 18 F-FDG) is extensively...
-
Amyloid PET scan diagnosis of Alzheimer’s disease in patients with multiple sclerosis: a sco** review study
BackgroundMultiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. This study aimed to evaluate the advantages and...
-
A pitfall of white matter reference regions used in [18F] florbetapir PET: a consideration of kinetics
ObjectiveMany studies have demonstrated the superiority of white matter (WM) reference regions (RR) in amyloid PET studies in comparison to...
-
Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease
The associations of synaptic loss with amyloid-β (Aβ) and tau pathology measured by positron emission tomography (PET) and plasma analysis in...
-
Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT
Background18 F-florbetapir PET is emerging as an excellent quantitative tool to quantify cardiac light chain (AL) amyloidosis burden. The primary aim ...
-
Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: A systematic review
PurposeTransthyretin (ATTR) amyloidosis is a progressive protein misfolding disease with frequent cardiac involvement. This review aims to determine...
-
-
A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer’s Disease Neuroimaging Initiative Cohort
BackgroundTo date, the clinical significance of visually equivocal amyloid positron emission tomography (PET) has not been well established.
...